Marksans Pharma UK arm gets MHRA nod for Metformin Hydrochloride Relonchem Prolonged Release Tablets in three strengths
Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Relonchem Limited in UK, has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for three strengths of its Metformin Hydrochloride Relonchem Prolonged Release Tablets.
The approved products include:
The latest approvals are part of a broader string of UK MHRA authorizations received by Relonchem throughout the year.
In June 2025, the subsidiary secured marketing authorization for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution.
The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK.
Back in February, Relonchem also received authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets (Bell's Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets).
Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA.
The company's product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.
